Droia Ventures
George Golumbeski is currently a partner at Droia Ventures. Prior to this, they served as an executive vice president of business development at Celgene from March 2009 to April 2018. In this role, they were responsible for in-licensing, strategic collaborations, mergers and acquisitions, out-licensing, and alliance management. George was also recognized for driving Celgene's collaboration strategy and "deal flow". Prior to Celgene, Golumbeski served as the vice president of business development, licensing, and strategy at Novartis from November 2002 to April 2008. George also served as the vice president of R&D business development at Elan Pharmaceuticals from May 2001 to August 2002. Golumbeski began their career in the pharmaceutical industry as the vice president of corporate development at Schwarz Pharma from October 1997 to December 2000.
George Golumbeski has a PhD in Genetics/Molecular Biology from the University of Wisconsin-Madison. George also has a BA in Biology from the University of Virginia.
George Golumbeski reports to Janwillem Naesens, Managing Partner. George Golumbeski works with Joke Vereecken - Principal, Evelien Verdrengh - Office Manager & Executive Assistant, and Heleen Boonen - Legal Counsel.
This person is not in any offices
Droia Ventures
1 followers
Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. They invest in novel science and innovative approaches to bring promising drug candidates to patients and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. Droia has an in-house team of experts and drug development professionals who follow the portfolio companies closely and provide hands-on support. Droia invests in early financing rounds and incubates new companies.